The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Open accessAbstract
The cognitive hallmark of early Alzheimer's disease (AD) is an extraordinary inability to form new memories. For many years, this dementia was attributed to nerve-cell death induced by deposits of fibrillar amyloid beta (Abeta). A newer hypothesis has emerged, however, in which early memory loss is considered a synapse failure caused by soluble Abeta oligomers. Such oligomers rapidly block long-term potentiation, a classic experimental paradigm for synaptic plasticity, and they are strikingly elevated in AD brain tissue and transgenic-mouse AD models. The current work characterizes the manner in which Abeta oligomers attack neurons. Antibodies raised against synthetic oligomers applied to AD brain sections were found to give diffuse stain around neuronal cell bodies, suggestive of a dendritic pattern, whereas soluble brain extracts showed robust AD-dependent reactivity in dot immunoblots. Antigens in unfractionated AD extracts attached with specificity to cultured rat hippocampal neurons, binding within dendritic arbors at discrete puncta. Crude fractionation showed ligand size to be between 10 and 100 kDa. Synthetic Abeta oligomers of the same size gave identical punctate binding, which was highly selective for particular neurons. Image analysis by confocal double-label immunofluorescence established that >90% of the punctate oligomer binding sites colocalized with the synaptic marker PSD-95 (postsynaptic density protein 95). Synaptic binding was accompanied by ectopic induction of Arc, a synaptic immediate-early gene, the overexpression of which has been linked to dysfunctional learning. Results suggest the hypothesis that targeting and functional disruption of particular synapses by Abeta oligomers may provide a molecular basis for the specific loss of memory function in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite ongoing debate, Aβ accumulation, whether in the form of insoluble plaques, or smaller soluble oligomers does appear to be a primary driver of the disease process, particularly linked to synapse dysfunction [3].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, overexpression of APP and its proteolytic product, Aβ, have been implicated in the synaptic losses seen early in the development of AD [27].”
From FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other suggested Aβ binding partners at synapses include the α7-nicotinic receptor [49], Ephrin A4 [73], PSD95 [35, 50, 52] and LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“As previously discussed, amyloid-β oligomers bind to synapses [144] and interfere with the normal process of neurotransmission, long-term potentiation, and thereby memory formation [145].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [144]
In the citing paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The same binding specificity and punctate pattern is observed for synthetic oligomers, particularly those greater than 50 kDa (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Oligomers show > 90% co-localization with the post-synaptic marker PSD-95 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“This prediction was first confirmed for NMDA-Rs (Lacor et al., 2004; Lacor et al., 2007; Snyder et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“One rapid consequence is an aberrant expression of Arc (Activity-Regulated Cytoskeletal associated protein; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“All of these processes are affected by Aβ oligomers in vitro, using primary neuronal cultures (12, 15, 36, 37).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [37]
In the citing paper
“Furthermore, extracellular Aβ1-42 oligomers preferentially target synapses when added to neurons [43, 91].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [91]
In the citing paper
“Other binding partners that have been suggested to bind Aβ include the α7-nicotinic receptor [49], Ephrin A4 (EphA4) [73], PSD95 [35, 50, 52] or LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Research works printed but not linked: 2
- Klein WL (2004) Cytotoxic intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer's disease as a case study. In: Protein misfolding, aggregation and conformational diseases (Uversky V, ed). New York: Kluwer Academic/Plenum, in press.
- 2002, Nat Rev Neurosci, 3, 824
Cited by
Sorted by citations
Items 301–400 of 949
Walker, L. C., LeVine, H., Mattson, M. P., & Jucker, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.06.010 · Cited by 90
APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy
Breyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0539-7 · Cited by 87
Current and future treatment of amyloid diseases
Ankarcrona, M., Winblad, B. G., Monteiro, C., Fearns, C., Powers, E. T., Johansson, J., Westermark, G. T., Presto, J., Ericzon, B. ‐., & Kelly, J. W. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12506 · Cited by 90
Micci, M., Krishnan, B., Bishop, E. A., Zhang, W.-R., Guptarak, J., Grant, A. C., Zolochevska, O., Tumurbaatar, B., Franklin, W. F., Mariño, C., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0322-8 · Cited by 88
Protein Folding and Misfolding on Surfaces
Stefani, M. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9122515 · Cited by 89
Simvastatin therapy prevents brain trauma‐induced increases in β‐amyloid peptide levels
Abrahamson, E. E., Ikonomović, M. D., Dixon, C. E., & DeKosky, S. T. (2009) · Annals of Neurology · doi:10.1002/ana.21731 · Cited by 89
Frizzled‐1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers
Chacón, M. A., Varela‐Nallar, L., & Inestrosa, N. C. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21497 · Cited by 87
Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro
Cascella, R., Conti, S., Mannini, B., Li, X., Buxbaum, J. N., Tiribilli, B., Chiti, F., & Cecchi, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.011 · Cited by 86
Inestrosa, N. C., Godoy, J. A., Vargas, J., Arrázola, M. S., Ríos, J. A., Carvajal, F. J., Serrano, F. G., & Farı́as, G. G. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8242-1 · Cited by 89
Canas, P. M., Simões, A. P., Rodrigues, R. J., & Cunha, R. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.026 · Cited by 86
Pitt, J. E., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X., Nandamuri, S., Gomes, F. C. A., DiNunno, N., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0416 · Cited by 87
Self-citationBeta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons
Kelly, B. L., & Ferreira, A. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.03.047 · Cited by 85
Nie, J., Tian, Y., Zhang, Y., Lu, Y.-L., Li, L., & Shi, J. (2016) · PeerJ · doi:10.7717/peerj.2739 · Cited by 85
Brito-Moreira, J., Lourenco, M. V., Oliveira, M. M., Ribeiro, F. C., Ledo, J. H., Diniz, L. P., Vital, J. F. S., Magdesian, M. H., Melo, H. M., Barros-Aragão, F., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761189 · Cited by 84
Evangelisti, E., Cecchi, C., Cascella, R., Sgromo, C., Becatti, M., Dobson, C. M., Chiti, F., & Stefani, M. (2012) · Journal of Cell Science · doi:10.1242/jcs.098434 · Cited by 84
Brody, D. L., Jiang, H., Wildburger, N. C., & Esparza, T. J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0293-3 · Cited by 86
Kaya, I., Jennische, E., Lange, S., Baykal, A. T., Malmberg, P., & Fletcher, J. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14999 · Cited by 85
Stefanova, N. A., Maksimova, K. Y., Владимировна, К. Е., Rudnitskaya, E. A., Muraleva, N. A., & Kolosova, N. G. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12248 · Cited by 84
Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
Faivre, É., & Hölscher, C. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt174 · Cited by 84
Pathogenesis of Abeta Oligomers in Synaptic Failure
Sivanesan, S., Tan, A., & Rajadas, J. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030011 · Cited by 85
Heo, C., Chang, K., Choi, H. S., Kim, H., Kim, S., Liew, H., Kim, J. A., Yu, E., Ma, J., & Suh, Y. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04499.x · Cited by 86
Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease
Wu, Z., Ciallella, J. R., Flood, D. G., O’Kane, T. M., Bozyczko‐Coyne, D., & Savage, M. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.010 · Cited by 84
Hoscheidt, S. M., Starks, E. J., Oh, J. M., Zetterberg, H., Blennow, K., Krause, R. A., Gleason, C. E., Puglielli, L., Atwood, C., Carlsson, C. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160110 · Cited by 84
scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease
Ma, K., Thomason, L. A. M., & McLaurin, J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00006-4 · Cited by 86
β-amyloid oligomers and cellular prion protein in Alzheimer’s disease
Gunther, E. C., & Strittmatter, S. M. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0568-7 · Cited by 84
Shemer, I., Holmgren, C. D., Min, R., Fülöp, L., Zilberter, M. Y., Sousa, K. M., Farkas, T., Härtig, W., Penke, B., Burnashev, N., et al. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04733.x · Cited by 86
Prion protein and Alzheimer disease
Kellett, K. A. B., & Hooper, N. M. (2009) · Prion · doi:10.4161/pri.3.4.9980 · Cited by 88
Narayan, P. S., Ganzinger, K. A., McColl, J. T., Weimann, L., Meehan, S., Qamar, S., Carver, J. A., Wilson, M. R., George‐Hyslop, P. S., Dobson, C. M., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3103567 · Cited by 85
Luchena, C., Zuazo-Ibarra, J., Alberdi, E. M., Matute, C., & Capetillo‐Zarate, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/2530414 · Cited by 84
Smith, L. M., Kostylev, M. A., Lee, S., & Strittmatter, S. M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006252 · Cited by 73
Chung, H., Park, K., Jang, H. J., Kohl, M. M., & Kwag, J. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02044-3 · Cited by 85
Intraneuronal amyloid β accumulation and oxidative damage to nucleic acids in Alzheimer disease
Nunomura, A., Tamaoki, T., Tanaka, K., Motohashi, N., Nakamura, M., Hayashi, T., Yamaguchi, H., Shimohama, S., Lee, H., Zhu, X., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.012 · Cited by 82
Bravo, R., Arimon, M., Valle‐Delgado, J. J., García, R., Durany, N., Castel, S., Cruz, M., Ventura, S., & Fernàndez‐Busquets, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709870200 · Cited by 79
Dietary fatty acids and the aging brain
Cole, G. M., Ma, Q., & Frautschy, S. A. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00345.x · Cited by 79
Pathology of clinical and preclinical Alzheimer’s disease
Thal, D. R., Arnim, C. A. F. V., Griffin, W. S. T., Yamaguchi, H., Mrak, R. E., Attems, J., & Upadhaya, A. R. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0449-5 · Cited by 80
Stefani, M. (2007) · The Neuroscientist · doi:10.1177/1073858407303428 · Cited by 77
Amyloid Toxicity Is Independent of Polypeptide Sequence, Length and Chirality
Pastor, M. T., Kuemmerer, N., Schubert, V., Esteras‐Chopo, A., Dotti, C. G., de la Paz, M. L., & Serrano, L. G. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.08.012 · Cited by 79
Godoy, J. A., Lindsay, C. B., Quintanilla, R. A., Carvajal, F. J., Cerpa, W. F., & Inestrosa, N. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0203-x · Cited by 78
Li, Y., Xu, D., Sun, A., Ho, S., Poon, C., Chan, H., Ng, O. T.-W., Yung, K. K. L., Yan, H., Li, H., et al. (2017) · Chemical Science · doi:10.1039/c7sc03974c · Cited by 77
Gong, Y., & Lippa, C. F. (2010) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317510382893 · Cited by 76
Self-citationBlocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer’s disease
Epis, R., Marcello, E. E., Gardoni, F., Vastagh, C., Malinverno, M., Balducci, C., Colombo, A. V., Borroni, B., Vara, H., Dell’Agli, M., et al. (2010) · Brain · doi:10.1093/brain/awq217 · Cited by 83
Head, E. (2010) · AGE · doi:10.1007/s11357-010-9183-3 · Cited by 81
Yamakawa, M. Y., Uchino, K., Watanabe, Y., Adachi, T., Nakanishi, M., Ichino, H., Hongo, K., Mizobata, T., Kobayashi, S., Nakashima, K., et al. (2015) · Nutritional Neuroscience · doi:10.1179/1476830515y.0000000042 · Cited by 75
Gao, L., Tian, M., Zhao, H., Xu, Q., Huang, Y. M., Si, Q., Tian, Q., Wu, Q., Hu, X., Sun, L., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13432 · Cited by 76
Haas, L. T., & Strittmatter, S. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720664 · Cited by 75
Kasza, Á., Penke, B., Frank, Z., Bozsó, Z., Szegedi, V., Hunya, Á. G., Németh, K., Kozma, G., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22112007 · Cited by 78
Carvedilol as a potential novel agent for the treatment of Alzheimer's disease
Wang, J., Ono, K., Dickstein, D. L., Arrieta‐Cruz, I., Zhao, W., Qian, X., Lamparello, A. J., Subnani, R., Ferruzzi, M. G., Pavlides, C., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.004 · Cited by 76
Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly
Umegaki, H., Hayashi, T., Nomura, H., Yanagawa, M., Nonogaki, Z., Nakshima, H., & Kuzuya, M. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2012.00922.x · Cited by 75
Gardoni, F., Marcello, E. E., & Luca, M. D. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.068 · Cited by 73
Lourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 74
Calkins, M. J., Mańczak, M., & Reddy, P. (2012) · Pharmaceuticals · doi:10.3390/ph5101103 · Cited by 71
Fuentealba, R. A., Barría, M. I., Lee, J., Cam, J., Araya, C., Escudero, C. A., Inestrosa, N. C., Bronfman, F. C., Bu, G., & Marzolo, M.-P. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-14 · Cited by 70
Hamilton, A., Zamponi, G. W., & Ferguson, S. S. G. (2015) · Molecular Brain · doi:10.1186/s13041-015-0107-0 · Cited by 72
Morales-Zavala, F., Arriagada, H., Hassan, N., Velasco, C., Riveros, A. L., Alvarez, A. R., Minniti, A. N., Rojas‐Silva, X., Muñoz, L. L., Vásquez, R. A., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.06.013 · Cited by 70
Cremades, N., & Dobson, C. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.009 · Cited by 72
Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid β-treated Rats
Mhillaj, E., Morgese, M. G., Tucci, P., Furiano, A., Luongo, L., Bové, M., Maione, S., Cuomo, V., Schiavone, S., & Trabace, L. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2017.12.046 · Cited by 72
Jakaria, M., Park, S., Haque, M. E., Karthivashan, G., Kim, I., Ganesan, P., & Choi, D. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00307 · Cited by 71
An update on drug treatment options of Alzheimer's disease
Allgaier, M. (2014) · Frontiers in bioscience · doi:10.2741/4285 · Cited by 69
Spencer, B. J., Marr, R. A., Gindi, R., Potkar, R., Michael, S. A., Adame, A., Rockenstein, E. M., Verma, I. M., & Masliah, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016575 · Cited by 69
Vargas, L. M., Cerpa, W. F., Muñoz, F. J., Zanlungo, S., & Alvarez, A. R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.023 · Cited by 71
Extracellular chaperones prevent Aβ42-induced toxicity in rat brains
Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., Wilson, M. R., Chiti, F., & Cecchi, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.012 · Cited by 70
Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders
Torres, V. I., Vallejo, D., & Inestrosa, N. C. (2017) · Neural Plasticity · doi:10.1155/2017/8081758 · Cited by 71
David, D. C., Ittner, L. M., Gehrig, P., Nergenau, D., Shepherd, C. E., Halliday, G. M., & Götz, J. (2006) · PROTEOMICS · doi:10.1002/pmic.200600634 · Cited by 68
Xu, W., Fitzgerald, S. M., Nixon, R. A., Levy, E., & Wilson, D. A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.008 · Cited by 69
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease
Lithner, C. U., Lacor, P. N., Zhao, W.-Q., Mustafiz, T., Klein, W. L., Sweatt, J. D., & Hernandez, C. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.028 · Cited by 67
Self-citationJang, H., Lee, S., Choi, S. L., Kim, H. Y., Baek, S., & Kim, Y. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1079-2_21 · Cited by 67
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Controlling β-Amyloid Oligomerization by the Use of Naphthalene Sulfonates
Gonzales, A. D. F., Robbs, B. K., Moreau, V. H., Ferreira, A., Juliano, L., Valente, A. P., Almeida, F. C. L., Silva, J. L., & Foguel, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501651200 · Cited by 67
Kim, J., Kim, M., Kang, S. M., Lim, K., Kim, T. S., & Kang, J. Y. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.10.042 · Cited by 66
Rahimi, F., Murakami, K., Summers, J. L., Chen, C. B., & Bitan, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007694 · Cited by 68
Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target
Inestrosa, N. C., Varela‐Nallar, L., Grabowski, C. P., & Colombres, M. (2007) · IUBMB Life · doi:10.1080/15216540701242490 · Cited by 65
Ding, Y. J., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C. F., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 68
Self-citationSynaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
Lipid raft disruption protects mature neurons against amyloid oligomer toxicity
Malchiodi‐Albedi, F., Contrusciere, V., Raggi, C., Fecchi, K., Rainaldi, G., Paradisi, S., Matteucci, A., Santini, M. T., Sargiacomo, M., Frank, C., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.01.007 · Cited by 65
Nag, S., Chen, J., Irudayaraj, J., & Maiti, S. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.07.020 · Cited by 66
Intracellular Trafficking Mechanisms of Synaptic Dysfunction in Alzheimer’s Disease
Perdigão, C., Barata, M. A., Araújo, M. N. C. D. F., Mirfakhar, F. S., Castanheira, J., & Almeida, C. G. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00072 · Cited by 66
Westmark, C. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.122 · Cited by 63
Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
Saura, C. A., Parra‐Damas, A., & Enríquez-Barreto, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00318 · Cited by 65
Meng, X. W., Li, T., Wang, X., Lv, X., Sun, Z., Zhang, J., Feng, S., Kang, S., Kim, S., An, S. S. A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0535-7 · Cited by 63
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific
Zago, W., Buttini, M., Comery, T. A., Nishioka, C., Gardai, S. J., Seubert, P., Games, D., Bard, F., Schenk, D., & Kinney, G. G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1676-11.2012 · Cited by 62
Severe Motor Neuron Degeneration in the Spinal Cord of the Tg2576 Mouse Model of Alzheimer Disease
Seo, J., Leem, Y., Lee, K.-W., Kim, S., Lee, J.-K., & Han, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091528 · Cited by 62
Amyloid-β oligomers regulate the properties of human neural stem cells through GSK-3β signaling
Lee, I.-S., Jung, K., Kim, I., & Park, K. I. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.125 · Cited by 63
Eslami, M., Sadeghi, B., & Goshadrou, F. (2018) · Hippocampus · doi:10.1002/hipo.23002 · Cited by 62
Armijo, E., González, C., Shahnawaz, M., Flores, A., Davis, B. R., & Soto, C. A. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.12.060 · Cited by 61
Rui, Y., Gu, J., Yu, K., Hartzell, H. C., & Zheng, J. Q. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-10 · Cited by 62
Meli, G., Visintin, M., Cannistraci, I., & Cattaneo, A. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.061 · Cited by 64
Marcello, E. E., Epis, R., & Luca, M. D. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.083 · Cited by 63
Wang, X.-P., Zhang, J.-H., Wang, Y.-J., Feng, Y. N., Zhang, X., Sun, X.-X., Li, J.-L., Du, X.-T., Lambert, M. P., Yang, S.-G., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.12.064 · Cited by 62
Self-citationEffects of different amyloid β-protein analogues on synaptic function
Ripoli, C., Piacentini, R., Riccardi, E., Leone, L., Puma, D. D. L., Bitan, G., & Grassi, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.027 · Cited by 62
Role of Sirt1 During the Ageing Process: Relevance to Protection of Synapses in the Brain
Godoy, J. A., Zolezzi, J. M., Braidy, N., & Inestrosa, N. C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8645-5 · Cited by 60
Skorobogatko, Y. V., Deuso, J., Adolf-Bergfoyle, J., Nowak, M. G., Gong, Y., Lippa, C. F., & Vosseller, K. (2010) · Amino Acids · doi:10.1007/s00726-010-0645-9 · Cited by 60
Self-citationFaivre, É., & Hölscher, C. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121888 · Cited by 60
Hong, H., Maezawa, I., Yao, N., Xu, B., Díaz-Avalos, R., Rana, S., Hua, D. H., Cheng, R. H., Lam, K. S., & Jin, L. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.093 · Cited by 60
Morris, J. C. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000167923.56275.d8 · Cited by 61
Sadleir, K. R., & Vassar, R. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333914 · Cited by 59
Wang, H., Megill, A., He, K., Kirkwood, A., & Lee, H. (2012) · Neural Plasticity · doi:10.1155/2012/272374 · Cited by 66
Kamal, M. A., Qu, X., Yu, Q., Tweedie, D., Holloway, H. W., Li, Y., Tan, Y., & Greig, N. H. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0022-y · Cited by 59
Xiao, C., Davis, F., Chauhan, B. C., Viola, K. L., Lacor, P. N., Velasco, P. T., Klein, W. L., & Chauhan, N. B. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122419 · Cited by 59
Self-citationMisfolded amyloid-β-42 impairs the endosomal–lysosomal pathway
Marshall, K. E., Vadukul, D. M., Staras, K., & Serpell, L. C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03464-4 · Cited by 61
Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Uddin, M. S., Mamun, A. A., Rahman, M. A., Behl, T., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200601161703 · Cited by 59
Metadata
- Authors
- Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- University of Southern California (US)
- Acumen Pharmaceuticals (United States) (US)
- Corresponding author
- Klein, William L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-11-10
- Volume
- 24
- Issue
- 45
- Pages
- 10191-10200
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6730194
- OpenAlex
- W2162807572
- Cited by
- 954
- References
- 64
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 28 · 2020: 26 · 2019: 32 · 2018: 41 · 2017: 50 · 2016: 51 · 2015: 50 · 2014: 54 · 2013: 65 · 2012: 59
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Illinois Department of Public Health
- Northwestern University
- National Institutes of Health (AG11385)
- National Institute on Aging (R01 AG11385, P30AG13854, R01AG022547, R01-AG22547, R01AG011385, R03AG022237, R01-AG18877, P30AG013854, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, synaptic targeting, long-term potentiation, synaptic plasticity, PSD-95, Arc, hippocampal neurons, memory loss, early Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Binding Sites, Cerebral Cortex, Cerebrospinal Fluid Proteins, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Female, Hippocampus, Humans, Male, Nerve Tissue Proteins, Neurons, Peptide Fragments, Protein Binding, Synapses, Tissue Extracts, Amyloid beta-Peptides, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
